Antibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
- Flow cytometry [1]
- Other assay [8]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 35-8100 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- COX1 Monoclonal Antibody (COX 111)
- Antibody type
- Monoclonal
- Antigen
- Other
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- COX 111
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- -20°C
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of human platelets using Mouse anti-COX-1 monoclonal antibody (clone COX 111) (Product # 35-8100).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on whole cell extracts (30 µg lysate) of Mouse Heart (Lane 1), NIH/3T3 (Lane 2), HT-29 (Lane 3), HCT 116 (Lane 4), C2C12 (Lane 5) and RAW 264.7 (Lane 6). The blots were probed with Anti-COX-1 Mouse Monoclonal Antibody (Product # 35-8100, 2-5 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP conjugate (Product # 62-6520, 1:4000 dilution). A 64 kDa band corresponding to COX-1 was observed across cell lines tested except HCT 116 and RAW 264.7. A 56 kDa band was observed in Mouse Heart. Known quantity of protein samples were electrophoresed using Novex® NuPAGE®10 % Bis-Tris gel (Product # NP0301BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of thyroid carcinoma tissue using COX-1 Monoclonal Antibody, Mouse (clone COX 111) (Product # 35-8100).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of COX-1 was done on NIH/3T3 cells. Cells were fixed with 70% ethanol for 10 minutes, permeabilized with 0.25% Triton™ X-100 for 20 minutes, and blocked with 5% BSA for 30 minutes at room temperature. Cells were labeled with COX-1 Mouse Monoclonal Antibody (358100, red histogram) or with mouse isotype control (yellow histogram) at 3-5 ug/million cells in 2.5% BSA. After incubation at room temperature for 2 hours, the cells were labeled with Alexa Fluor® 488 Rabbit Anti-Mouse Secondary Antibody (A11059) at a dilution of 1:400 for 30 minutes at room temperature. The representative 10,000 cells were acquired and analyzed for each sample using an Attune® Acoustic Focusing Cytometer. The purple histogram represents unstained control cells and the green histogram represents no-primary-antibody control.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Fluorescent immunocytochemistry was performed on cytospun BAL-cells using monoclonal antibodies against COX-1, COX-2, 15-LOX-1 and PPARgamma coupled with secondary antibodies labeled with fluorescent dyes Alexa488 (green) and Cy5 (red). Nuclear counter-staining was performed using DAPI (blue). Representative micrographs from a healthy and an asthmatic individual are shown for both the control air (A) and subway air (B) exposures. Semi-quantitative evaluation of staining intensities was performed using ImageJ software [24] .
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 7 Correlation between cyclooxygenase and CXCL9 expression in human breast cancer tissue samples . Homogenates were prepared from deep-frozen breast cancer tissue samples and analyzed for COX-1 and COX-2 expression by western blot analysis. Panel a shows representative immunoblots with high (first lane) and low (second lane) expression of both enzymes. For both cyclooxygenase isoenzymes samples were divided into a low and a high expressing group (see text for further details), and CXCL9 concentration was determined in all samples by ELISA. There was a trend towards lower CXCL9 expression in the high COX-1 expressing group ( b ; n low = 22, n high = 21), but a significantly reduced CXCL9 concentration in highly COX-2 expressing breast cancers ( c ; n low = 12, n high = 17). COX-2 overexpressing breast cancers display only half of the average CXCL9 concentration found in low-expressing cancers (56.5% +- 13.9%). (b and c) CXCL9/total protein ratio is presented as arbitrary units with 1.0 set as the arithmetic mean of the low expressing group. Horizontal lines in b and c represent the arithmetic mean.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Protein expressions of COX1 ( A ) and COX2 ( B ) in the aortas of wild-type (WT) littermates and eAPP -/- mice. Western blot results are the relative densitometry compared with beta-actin protein (n=10 per group for COX1 and n=8 per group for COX2). All results are representing box plots with whiskers showing the median, 25 th to 75 th percentiles, and min-max range. * P
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 Mortaparib-treated HeLa cells undergo apoptosis. Flow cytometric analysis showing increase in apoptotic cells in dose dependent manner following Mortaprib treatment ( a ). Western blot analysis showing molecular markers of apoptosis in control and Mortaparib-treated cells ( b ). Decrease in pro-caspase, BCl2, COX I, COX IV, Caspase-7, - 9, - 10 in Mortaparib-treated cells was recorded. Cleaved caspase-3 showed increase. Immunostaining showed decrease in COX I, COX IV, Procaspase 3 and BCl2 proteins in Mortaparib-treated cells (Scale bar = 20 muM). c . Caspase-3 activity, as evaluated using a fluoremetric assay, showed increase in dose-dependent manner ( d ). The quantitative data represents mean +- SD obtained from, at least, three independent experiments; p -values were calculated using Student's t -test. * < 0.05, ** < 0.01 and *** < 0.001 represent significant, very significant and very very significant, respectively